Evidence map›Paper›PMID 38530799›Full record

ArticleQJM : monthly journal of the Association of Physicians2024

Regional European genetic ancestry predicts type I interferon level and risk of severe viral infection.

I Nln, J Shum, Y Ghodke-Puranik, R Tipon, D Triese, S Amin, A Makol, T Osborn, V Chowdhary, U Thanarajasingam and 9 more

Abstract read
In one paragraph

Article in QJM : monthly journal of the Association of Physicians, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

I NlnDivision of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, NY, USA.
J ShumDepartment of Medicine, MarinHealth Medical Center, Kentfield, CA, USA.
Y Ghodke-PuranikDivision of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, NY, USA.
R TiponThe New York Stem Cell Foundation, New York, NY, USA.
D TrieseDivision of Rheumatology, Mayo Clinic, Rochester, MN, USA.
S AminDivision of Rheumatology, Mayo Clinic, Rochester, MN, USA.
A MakolDivision of Rheumatology, Mayo Clinic, Rochester, MN, USA.
T OsbornDivision of Rheumatology, Mayo Clinic, Rochester, MN, USA.
V ChowdharyDivision of Rheumatology, Yale University, New Haven, CT, USA.ORCID 0000-0003-4626-2412
U ThanarajasingamDivision of Rheumatology, Mayo Clinic, Rochester, MN, USA.
T L W MuskardinDivision of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, NY, USA.
V OkeDivision of Rheumatology, Department of Medicine Solna, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
I GunnarssonDivision of Rheumatology, Department of Medicine Solna, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
A ZickertDivision of Rheumatology, Department of Medicine Solna, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
M I ZervouLaboratory of Molecular Medicine and Human Genetics, Department of Internal Medicine, School of Medicine, University of Crete, Heraklion, Greece.
D T BoumpasBiomedical Research Foundation, Academy of Athens, Athens, Greece.
E SvenungssonDivision of Rheumatology, Department of Medicine Solna, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.ORCID 0000-0003-3396-3244
G N GoulielmosLaboratory of Molecular Medicine and Human Genetics, Department of Internal Medicine, School of Medicine, University of Crete, Heraklion, Greece.
T B NiewoldDivision of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, NY, USA.

Funding

Interferon Regulatory Factor 5 in Human Lupus PathogenesisR01AR065964 · NIAMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI NIEWOLD, TIMOTHY B · 2015 to 2018
$2.0M
Type I interferon Impacts Treatment Response in Rheumatoid ArthritisK08AI166075 · NIAID · HOSPITAL FOR SPECIAL SURGERY · PI Theresa Wampler Muskardin · 2022 to 2026
$988k
Arthritis National Research FoundationIngegerd Johansson Donation SLS-713911Lupus Research AllianceLupus Research FoundationNIAID NIH HHS K08 AI166075NIAMS NIH HHS L30 AR084819NIAMS NIH HHS R01 AR065964NIH HHS AI164968NIH HHS AI166075Stockholm Region ALF Funding 20200075Swedish Research Council 2018-02535Swedish Society of Medicine
6 · The paper itself

Abstract

backgroundViral infection outcomes vary widely between individuals, ranging from mild symptoms to severe organ failure and death, and it is clear that host genetic factors play a role in this variability. Type I interferon (IFN) is a critical anti-viral cytokine, and we have previously noted differences in type I IFN levels between world populations.

methodsIn this study, we investigate the interrelationship between regional European genetic ancestry, type I IFN levels and severe viral infection outcomes.

resultsIn cohorts of European ancestry lupus patients living in Europe, we noted higher IFN in the Northwestern populations as compared to Southeastern populations. In an independent cohort of European ancestry lupus patients from the USA with varying proportional regional European genetic admixture, we observed the same Northwest vs. Southeast European ancestry IFN gradient. We developed a model to predict type I IFN level based on regional European ancestry (Area under the curve (AUC) = 0.73, P = 6.1e-6). Examining large databases containing serious viral outcomes data, we found that lower predicted IFN in the corresponding European country was significantly correlated with increased viral infection fatality rate, including Coronavirus Disease 2019 (COVID-19), viral hepatitis and HIV [correlation coefficients: -0.79 (P = 4e-2), -0.94 (P = 6e-3) and -0.96 (P = 8e-2), respectively].

conclusionsThis association between predicted type I IFN level and viral outcome severity suggests a potential causal relationship, as greater intrinsic type I IFN is beneficial in host defense against viruses. Genetic testing could provide insight into individual and population level risk of fatality due to viruses prior to infection, across a wide range of viral pathogens.

Indexed as

Interferon Type IVirus DiseasesWhite PeopleAdultCOVID-19EuropeFemaleHumansLupus Erythematosus, SystemicMaleMiddle AgedSeverity of Illness IndexUnited StatesInterferon Type I

Identifiers

PMID38530799
PMCPMC11389909

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.